Accès gratuit
Med Sci (Paris)
Volume 25, Numéro 1, Janvier 2009
Page(s) 45 - 50
Section M/S revues
Publié en ligne 15 janvier 2009
  1. Mezyk R, Bzowska M, Bereta J. Structure and functions of tumor necrosis factor-alpha converting enzyme. Acta Biochim Pol 2003; 50 : 625–45.
  2. Huovila APJ, Turner AJ, Pelto-Huikko M, et al. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005; 30 : 413–22.
  3. Blobel CP. ADAMS : key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6 : 32–43.
  4. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29 : 258–89.
  5. Alfandari D, Cousin H, Gaultier A, Darribère T. Les protéines de la famille ADAM : protéolyse, adhérence et signalisation. Med Sci (Paris) 1999; 15 : 1148–51.
  6. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour necrosis factor-alpha from cells. Nature 1997; 385 : 729–33.
  7. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385 : 733–6.
  8. Peiretti F, Deprez-Beauclair P, Bonardo B, et al. Identification of SAP97 as an intracellular binding partner of TACE. J Cell Sci 2003; 116 : 1949–57.
  9. Canault M, Tellier E, Bonardo B, et al. FHL2 interacts with both ADAM-17 and the cytoskeleton and regulates ADAM-17 localization and activity. J Cell Physiol 2006; 208 : 363–72.
  10. Soond SM, Everson B, Riches DWH, Murphy G. ERK-mediated phosphorylation of Thr735 in TNF(alpha)-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 2005; 118 : 2371–80.
  11. Milla ME, Gonzales PE, Leonard JD. The TACE zymogen : re-examining the role of the cysteine switch. Cell Biochem Biophys 2006; 44 : 342–8.
  12. Peiretti F, Canault M, Deprez-Beauclair P, et al. Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme. Exp Cell Res 2003; 285 : 278–85.
  13. Sagi I, Milla ME. Application of structural dynamic approaches provide novel insights into the enzymatic mechanism of the tumor necrosis factor-(alpha)-converting enzyme. Anal Biochem 2008; 372 : 1–10.
  14. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435 : 39–44.
  15. Matthews V, Schuster B, Schutze S, et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003; 278 : 38829–39.
  16. Tellier E, Canault M, Rebsomen L, et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res 2006; 312 : 3969–80.
  17. Eissner G, Kolch W, Scheurich P. Ligands working as receptors : reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004; 15 : 353–66.
  18. Horiuchi K, Kimura T, Miyamoto T, et al. Cutting edge : TNF-(alpha)-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol 2007; 179 : 2686–9.
  19. Li N, Boyd K, Dempsey PJ, Vignali DAA. Non-cell autonomous expression of TNF-(alpha)-converting enzyme ADAM17 is required for normal lymphocyte development. J Immunol 2007; 178 : 4214–21.
  20. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997; 158 : 438–45.
  21. Mueller C, Corazza N, Trachsel-Loseth S, et al. Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNF alpha) mediates effects distinct from those of wild-type TNF alpha in vitro and in vivo. J Biol Chem 1999; 274 : 38112–8.
  22. Olleros ML, Guler R, Corazza N, et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-(alpha). J Immunol 2002; 168 : 3394–401.
  23. Voros G, Maquoi E, Collen D, Lijnen HR. Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-(alpha), TNF-(alpha) converting enzyme and ADAMTS family members in murine fat territories. Biochim Biophys Acta 2003; 1625 : 36–42.
  24. Smookler DS, Mohammed FF, Kassiri Z, et al. Cutting edge : tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 2006; 176 : 721–5.
  25. Tang ZY, Loss G, Carmody I, Cohen AJ. TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats. Transplantation 2006; 82 : 1518–23.
  26. Purcell MK, Mu JL, Higgins DC, et al. Fine mapping of Ath6, a quantitative trait locus for atherosclerosis in mice. Mamm Genome 2001; 12 : 495–500.
  27. Holdt LM, Thiery J, Breslow JL, Teupser D. Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008; 28 : 1097–103.
  28. Canault M, Peiretti F, Kopp F, et al. The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice : possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 2006; 187 : 82–91.
  29. Canault M, Leroyer AS, Peiretti F, et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-(alpha) converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 2007; 171 : 1713–23.
  30. Canault M, Peiretti F, Poggi M, et al. Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF-alpha. J Pathol 2008; 214 : 574–83.
  31. Fedak PWM, Moravec CS, McCarthy PM, et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006; 113 : 238–45.
  32. Shimoda Y, Satoh M, Nakamura M, et al. Activated tumour necrosis factor-alpha shedding process is associated with in-hospital complication in patients with acute myocardial infarction. Clin Sci (Lond) 2005; 108 : 339–47.
  33. Morange P, Tregouet D, Godefroy T, et al. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality : the Athero Gene study. J Mol Med 2008; 86 : 1153–61.
  34. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000; 32 (suppl 1) : 78–84.
  35. Xu H, Uysal KT, Becherer JD, et al. Altered tumor necrosis factor-(alpha) (TNF-[alpha]) processing in adipocytes and increased expression of transmembrane TNF-(alpha) in obesity. Diabetes 2002; 51 : 1876–83.
  36. Xu H, Hirosumi J, Uysal KT, et al. Exclusive action of transmembrane TNF(alpha) in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology 2002; 143 : 1502–11.
  37. Lee K, Villena JA, Moon YS, et al. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J Clin Invest 2003; 111 : 453–61.
  38. Serino M, Menghini R, Fiorentino L, et al. TNF-alpha converting enzyme heterozygous mice are protected from obesity-induced insulin resistance and diabetes. Diabetes 2007; 56 : 2541–6.
  39. Togashi N, Ura N, Higashiura K, et al. Effect of TNF-(alpha)-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 2002; 39 : 578–80.
  40. Gelling RW, Yan W, Al-Noori S, et al. Deficiency of TNF(alpha) converting enzyme (TACE/ADAM17) causes a lean, hypermetabolic phenotype in mice. Endocrinology 2008; 149 : 6053–64.
  41. Federici M, Hribal ML, Menghini R, et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 2005; 115 : 3494–505.
  42. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight : tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 2008; 4 : 300–9.
  43. Surena AL, de Faria GP, Studler JM, et al. DLG1/SAP97 modulates transforming growth factor alpha bioavailability. Biochim Biophys Acta 2008, 27 septembre online.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.